Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q2 2025 · 10-Q
Revenue$158.81M$158.81M+5.6% vs Q2 2024 Net Income-$40.14M-$40.14MN/M vs Q2 2024 EPS Diluted-$0.36-$0.36N/M vs Q2 2024 Gross Profit$117,333,000+1.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$15,936,000N/M Free Cash Flowderived-$21,422,000N/M Margins · derivedGross margin73.9%−3.1 pt vs Q2 2024
Operating margin-24.9%−2.6 pt vs Q2 2024
Net margin-25.3%−3.1 pt vs Q2 2024
ended Jun 30, 2025 · filed Jul 24, 2025 · 24 d after period end